Despite the availability of COVID-19 vaccines, additional more potent vaccines are still required against the emerging variations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the present investigation, we have identified a promising vaccine candidate against the Omicron (B.1.1.529) using immunoinformatics approaches. Various available tools like, the Immune Epitope Database server resource, and NetCTL-1.2, have been used for the identification of the promising T-cell and B-cell epitopes. The molecular docking was performed to check the interaction of TLR-3 receptors and validated 3D model of vaccine candidate. The codon optimization was done followed by cloning using SnapGene. Finally, In-silico immune simulation profile was also checked. The identified T-cell and B-cell epitopes have been selected based on their antigenicity (VaxiJen v2.0) and, allergenicity (AllerTOP v2.0). The identified epitopes with antigenic and non-allergenic properties were fused with the specific peptide linkers. In addition, the 3D model was constructed by the PHYRE2 server and validated using ProSA-web. The validated 3D model was further docked with the Toll-like receptor 3 (TLR3) and showed good interaction with the amino acids which indicate a promising vaccine candidate against the Omicron variant of SARS-CoV-2. Finally, the codon optimization, In-silico cloning and immune simulation profile was found to be satisfactory. Overall, the designed vaccine candidate has a potential against variant of SARS-Cov-2. However, further experimental studies are required to confirm.

No abstract

Backgrounds: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukaemia (CML) patients. The exact association of imatinib with anaemia in CML patients is still unclear. Aim: The current study aimed to find the prevalence of anaemia in chronic myeloid leukaemia patients treated with imatinib. Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% C. I was calculated using StatsDirect Statistical analysis software V.3. Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anaemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The monitoring of hemoglobin level and identifying the cause of anemia is major concern for the CML patients treated with Imatinib.